LegalizeS.I. No. 584/2023 - Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 7) Regulations 2023
This is the act as published. Later amendments are not folded into the text below: each one is a separate act in this repository and an entry in this law's history.
1 amending act · 2026-09-08, S.I. No. 457/2026 - Medicinal Products (Prescription and Control of Supply) (Amendment) R…
Notice of the making of this Statutory Instrument was published in
“Iris Oifigiúil” of 1st December, 2023.
I, STEPHEN DONNELLY, in exercise of the powers conferred on me by section 32 (as amended by section 16 of the Irish Medicines Board (Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make the following regulations:
1.
(1) These Regulations may be cited as the Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 7) Regulations 2023.
- (2) The collective citation “the Medicinal Products (Prescription and Control of Supply) Regulations 2003 to 2023” includes these Regulations.
2.
In these Regulations—
“Principal Regulations” means the Medicinal Products (Prescription and Control of Supply) Regulations 2003 ( S.I. No. 540 of 2003 );
“Regulations of 2023” means the Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 6) Regulations 2023 ( S.I. No. 451 of 2023 ).
3.
The Eighth Schedule (as amended by Regulation 3 of the Regulations of 2023) to the Principal Regulations is amended by inserting the following entry:
“
Medicinal Product Form and presentation of product administered Route of administration Indication for which the medicinal product may be administered Dosage and conditions of administration Place of administration Column 1 Column 2 Column 3 Column 4 Column 5 Column 6 Nuvaxovid XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) Dispersion for injection The dispersion is colourless to slightly yellow, clear to mildly opalescent (pH 7.2) Intramuscular injection Active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older. In accordance with the summary of product characteristics of the product administered and/or relevant national guidelines issued by the National Immunisation Advisory Committee. Any suitable and appropriate place, having regard to public convenience and the need to protect the health and safety of the public and safely administer the product. ”.
4.
The Twelfth Schedule (as amended by Regulation 4 of the Regulations of 2023) to the Principal Regulations is amended by inserting the following entry:
“
Medicinal product Form and presentation of product administered Route of administration Indication for which the medicinal product may be administered Dosage and conditions of administration Column 1 Column 2 Column 3 Column 4 Column 5 Nuvaxovid XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) Dispersion for injection The dispersion is colourless to slightly yellow, clear to mildly opalescent (pH 7.2) Intramuscular injection Active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older. In accordance with the summary of product characteristics of the product administered and/or relevant national guidelines issued by the National Immunisation Advisory Committee. ”.
GIVEN under my Official Seal,
29 November, 2023.
STEPHEN DONNELLY,
Minister for Health.
EXPLANATORY NOTE
(This note is not part of the Instrument and does not purport to be a legal interpretation.)
These Regulations amend the Medicinal Products (Prescription and Control of Supply) Regulations 2003.
The purpose of these Regulations is to update the relevant schedules in relation to the COVID-19 vaccines to include the Nuvaxovid XBB.1.5 COVID-19 vaccine.
These Regulations may be cited as the Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 7) Regulations 2023.
This document does not substitute the official text published in the Irish Statute Book. We accept no responsibility for any inaccuracies arising from the transcription of the original into this format.
This text is published under Irish Statute Book's own terms of reuse, not a Legalize or public-domain licence.
Irish Statute Book
CC-BY 4.0 (Oireachtas Open Data PSI Licence)
Contains Irish Public Sector Information licensed under the Oireachtas (Houses of the Oireachtas) Open Data PSI Licence / Creative Commons Attribution 4.0 International, sourced from https://www.irishstatutebook.ie.